Global biopharmaceutical company Takeda plans to introduce more than 15 innovative medicines in China in the next five years as part of its commitment to support the "Healthy China 2030" initiative.
The company estimated that these medicines will benefit around 10 million patients suffering from complex and rare diseases in China.
"We remain highly optimistic about China's pharmaceutical market," said Sean Shan, president of Takeda China, during the 3rd China International Import Expo. "The rapid recovery of the Chinese economy from the COVID-19 pandemic has confirmed the close connection between public health and economic development."
One highlight of Takeda's exhibition at the CIIE is the range of new products that are expected to be approved in China soon. These products are mainly related to the field of rare diseases, such as hereditary angioedema and the Gaucher disease.
Takeda has also joined hands with world-leading plasma companies to set up the CoVIg-19 Plasma Alliance to help develop a potential plasma-derived therapy for people at risk of serious complications from COVID-19.
"The hosting of the CIIE has forged a global, innovative ecosystem of circulation," Shan said. "We will continue to invest in China to introduce more global debuts and innovative therapies."
